Direkt zum Inhalt
Merck
  • Preparation & characterization of solid inclusion complex of cefpodoxime proxetil with beta-cyclodextrin.

Preparation & characterization of solid inclusion complex of cefpodoxime proxetil with beta-cyclodextrin.

Current drug delivery (2008-01-29)
S Bhargava, G P Agrawal
ZUSAMMENFASSUNG

Cefpodoxime proxetil (CPDX-PR) is an oral cephalosporin antibiotic with poor aqueous solubility and bioavailability. Effect of beta-cyclodextrin on aqueous solubility and dissolution rate of cefpodoxime proxetil was evaluated by the formation of solid inclusion complexes in 1:2 molar ratio of drug: cyclodextrin. Phase solubility study was carried out whereby a typical B's type curve was obtained thus, indicating a 1:2 stoichiometric ratio for optimum complex formation. Solid inclusion complexes in 1:2 molar ratios were prepared by using methods such as physical mixture, solvent evaporation and freeze drying. Prepared complexes were characterized by fourier transform infrared spectroscopy (FT-IR) differential scanning calorimetry (DSC), powder x-ray diffraction (PXRD) and scanning electron microscopy (SEM). Results of in vitro studies appraised of an increased solubility and dissolution rate of cefpodoxime proxetil on complexation with beta- cyclodextrin (P < 0.05) as compared to CPDX-PR alone. Amongst the complexes prepared by different methods, the complex prepared by freeze drying showed the highest dissolution rate (P< 0.01). The in vitro antimicrobial activity of cefpodoxime proxetil and its freeze dried complex (1:2) was studied against both antibiotic-susceptible and antibiotic-resistant clinical isolates of Neisseria gonorrhoeae. The freeze dried complex (1:2) inhibited all penicillin-susceptible strains and penicillinase-producing strains at 0.015 microg/ml concentration. Chromosomally resistant strains which were not responsive to penicillin were inhibited by the complex at 0.125 microg/ml concentration. The study revealed that complexation of cefpodoxime proxetil with beta-cyclodextrin effectively enhanced the aqueous solubility and in vitro antibacterial activity.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

USP
Cefpodoximproxetil, United States Pharmacopeia (USP) Reference Standard
Cefpodoximproxetil, European Pharmacopoeia (EP) Reference Standard
Cefpodoximproxetil für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Cefpodoximproxetil für die Identifizierung von Unreinheit H, European Pharmacopoeia (EP) Reference Standard